jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

TURP-Prostate Biopsy Small 1cm

Biopsy
image

Report in 240Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histology after resection.

₹296₹423

30% OFF

TURP-Prostate Biopsy Small 1cm - Comprehensive Test Guide

  • Why is it done?
    • Test Description: A minimally invasive procedure that obtains small tissue samples (approximately 1cm) from the prostate gland using a transurethral resection technique to diagnose prostate pathology.
    • Primary Indications: Suspected prostate cancer diagnosis when PSA levels are elevated, abnormal digital rectal examination findings, or persistent lower urinary tract symptoms
    • Diagnostic Assessment: Evaluates for malignancy, benign prostatic hyperplasia (BPH), prostatitis, and other pathological conditions affecting prostate tissue
    • Typical Timing: Performed when initial screening tests or imaging suggest prostate abnormalities, typically after age 50 or 40 for high-risk patients
    • Clinical Circumstances: Persistent symptoms unresponsive to conservative treatment, family history of prostate cancer, or patient anxiety regarding prostate health requiring definitive diagnosis
  • Normal Range
    • Negative Result: Histopathology shows benign prostate tissue with no evidence of adenocarcinoma, dysplasia, or malignancy present
    • Benign Findings: Benign prostatic hyperplasia (BPH), chronic prostatitis, atrophic glands, or normal prostatic tissue without concerning features
    • Reference Units: Tissue diagnosis reported as histopathological findings with Gleason Score if malignancy is present (ranging from 2-10)
    • Interpretation Framework: Negative/Normal = no malignancy detected; Positive = cancer confirmed with grading; Benign = non-cancerous findings
    • Clinical Significance: Normal results provide reassurance but do not completely exclude cancer in all areas; additional sampling may be warranted if clinical suspicion remains high
  • Interpretation
    • Adenocarcinoma Diagnosis: Presence of malignant glandular epithelium indicates prostate cancer; Gleason score provides grading (lower score = better prognosis, higher score = more aggressive)
    • Gleason Score Interpretation: Scores 2-4 (well-differentiated, low risk); 5-6 (intermediate differentiation); 7 (moderately aggressive); 8-10 (poorly differentiated, high risk/aggressive)
    • Inflammatory Findings: Acute or chronic prostatitis indicates infection/inflammation; requires antibiotic therapy and urological follow-up; can elevate PSA levels
    • High-Grade Dysplasia (PIN): Prostatic intraepithelial neoplasia represents pre-cancerous changes; increases risk of future malignancy; requires closer monitoring and possible repeat biopsy
    • Factors Affecting Results: Biopsy site sampling variation, inflammation from recent procedures, prostate size/architecture, specimen adequacy, and pathologist expertise influence accuracy
    • Result Limitations: Negative result does not absolutely exclude cancer (sampling error); focal lesions may be missed; repeat biopsy warranted if high clinical suspicion persists
    • Tissue Adequacy: Pathology report indicates if specimen is adequate for diagnosis; inadequate samples may require repeat biopsy procedure
  • Associated Organs
    • Primary Organ: Prostate gland (walnut-sized gland surrounding the urethra in males that produces seminal fluid)
    • Associated Structures: Urethra, seminal vesicles, bladder, rectum, and surrounding pelvic tissues; potential metastatic involvement to lymph nodes, bones, and distant organs
    • Prostate Cancer Associations: Advanced disease may involve seminal vesicles, pelvic side walls, obturator lymph nodes, and paraaortic lymph nodes
    • Complications of Abnormal Results: Urinary obstruction, erectile dysfunction, urinary incontinence, hematuria, hematospermia, and lower urinary tract symptoms if cancer spreads or compresses surrounding structures
    • Disease Associations: Prostate adenocarcinoma, benign prostatic hyperplasia (BPH), chronic prostatitis, acute bacterial prostatitis, and other epithelial malignancies
    • System Impact: Genitourinary system involvement; potential systemic effects if malignancy is detected including treatment-related side effects and quality of life implications
  • Follow-up Tests
    • If Cancer Diagnosed: PSA level quantification, bone scan/skeletal scintigraphy, CT scan of pelvis and abdomen, MRI prostate with endorectal coil, and biomarker testing for staging and treatment planning
    • If Benign Results: Repeat PSA testing in 3-6 months, continued clinical follow-up, urinalysis if infection suspected, and consideration for repeat biopsy if clinical suspicion remains
    • If High-Grade Dysplasia Found: Repeat biopsy within 3-6 months, close PSA surveillance every 3 months initially, possible targeted MRI-guided rebiopsy, and urological reassessment
    • Monitoring Schedule: Cancer patients: quarterly PSA levels first year, then semi-annual or annual based on stage; benign findings: annual PSA and digital rectal exam; dysplasia: every 3-6 months
    • Complementary Testing: 4Kscore test, PHI (Prostate Health Index), genomic biomarkers, mpMRI (multiparametric MRI), and transrectal ultrasound for targeted rebiopsy guidance
    • Treatment Planning Tests: Hormone receptor status testing, testosterone levels, renal function tests, and comprehensive metabolic panel before therapy initiation
    • Inadequate Specimen: Repeat TURP biopsy or alternative sampling technique (trans-rectal ultrasound-guided biopsy, transperineal approach) to obtain adequate diagnostic tissue
  • Fasting Required?
    • Fasting Requirement: NO - Fasting is not required for TURP-prostate biopsy; however, NPO (nothing by mouth) status for 6-8 hours may be recommended if general or regional anesthesia is planned
    • Anesthesia Considerations: If regional anesthesia (spinal) or general anesthesia used, follow standard NPO guidelines (no food 6 hours before, no clear liquids 2 hours before procedure)
    • Anticoagulation Management: Discontinue aspirin 5-7 days before procedure; hold warfarin 3-5 days before and check INR; hold direct oral anticoagulants (DOACs) 24-48 hours before; consult with prescribing physician
    • Antibiotic Prophylaxis: Fluoroquinolone or cephalosporin antibiotic typically administered 30-60 minutes before procedure; may continue for 24-48 hours post-procedure to prevent infection
    • Pre-procedure Preparation: Void bladder completely before procedure; wear loose, comfortable clothing; arrange transportation as driving not permitted after sedation; sign informed consent
    • Medications to Continue: Continue essential cardiac and blood pressure medications with sip of water; continue diabetes medications unless otherwise instructed; notify provider of all medications
    • Post-procedure Instructions: Expect mild hematuria, hematospermia for 1-2 weeks; increase fluid intake; avoid heavy lifting for 3-5 days; resume regular diet same day if no nausea; watch for signs of infection

How our test process works!

customers
customers